ArticleDermatology practical & conceptual2024

A prospective Real-Life Multicenter Study of Tildrakizumab 200 mg in Patients with Moderate-Severe Psoriasis: Who is the Ideal Patient?

Eugenia Veronica Di Brizzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.